Prognostic Staging of Extensively Pretreated Patients with Advanced HIV-1 Disease
作者： Julio Montaner , Denise Guimaraes , Jain Chung , Zarina Gafoor , Miklos Salgo
DOI: 10.1310/0XH7-F2V2-1K0R-NU2W
关键词: Immunology 、 Human immunodeficiency virus (HIV) 、 In patient 、 Regimen 、 Internal medicine 、 Medicine 、 Confidence interval 、 Viral load 、 Disease 、 Odds ratio 、 Enfuvirtide
摘要: AbstractPurpose: Determinants of therapeutic success are poorly characterized in patients with extensive HAART experience. Positive prognostic factors (PPFs) the TORO trials could serve as basis for a prognostically meaningful staging treatment-experienced initiating new antiretroviral regimen. Method: In TORO, triple-class-experienced viral load (VL) ≥5,000 copies/mL received an optimized background regimen 3-5 antiretrovirals (based on treatment history and baseline resistance testing) ± enfuvirtide (n = 995). Clinically relevant PPFs that were predictive 48-week virologic outcomes identified via multiple regression analyses. Results: The likelihood VL <400 at 48 weeks (ITT analysis) was greater those who had CD4 count ≥100 cells/mm3 (odds ratio [OR] 2.1; 95% confidence intervals [CIs] 1.5, 3.1); <5 log10 (OR 1.8; CIs 1.2, 2.6); ≤10 prior 2.4; 1.6, 3.4)...
sci-hub.se 参考文章(11)
Matthias Egger, Margaret May, Geneviève Chêne, Andrew N Phillips, Bruno Ledergerber, François Dabis, Dominique Costagliola, Antonella D'Arminio Monforte, Frank De Wolf, Peter Reiss, Jens D Lundgren, Amy C Justice, Schlomo Staszewski, Catherine Leport, Robert S Hogg, Caroline A Sabin, M John Gill, Bernd Salzberger, Jonathan AC Sterne, None, Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. The Lancet. ,vol. 360, pp. 119- 129 ,(2002) , 10.1016/S0140-6736(02)09411-4
Julio S.G. Montaner, John W. Mellors, Antiretroviral Therapy for Previously Treated Patients The New England Journal of Medicine. ,vol. 345, pp. 452- 455 ,(2001) , 10.1056/NEJM200108093450610
Andrew N. Phillips, Veronica Miller, Caroline Sabin, Alessandro Cozzi Lepri, Stephan Klauke, Markus Bickel, Hans Wilhelm Doerr, Andrew Hill, Schlomo Staszewski, Durability of HIV-1 viral suppression over 3.3 years with multi-drug antiretroviral therapy in previously drug-naive individuals. AIDS. ,vol. 15, pp. 2379- 2384 ,(2001) , 10.1097/00002030-200112070-00005
Steven G. Deeks, Nicholas S. Hellmann, Robert M. Grant, Neil T. Parkin, Christos J. Petropoulos, Mark Becker, William Symonds, Margaret Chesney, Paul A. Volberding, Novel Four-Drug Salvage Treatment Regimens after Failure of a Human Immunodeficiency Virus Type 1 Protease Inhibitor-Containing Regimen: Antiviral Activity and Correlation of Baseline Phenotypic Drug Susceptibility with Virologic Outcome The Journal of Infectious Diseases. ,vol. 179, pp. 1375- 1381 ,(1999) , 10.1086/314775
Hans-Jürgen Stellbrink, Jean-François Delfraissy, Joep Lange, Les Huson, Ralph DeMasi, Cynthia Wat, John Delehanty, Claude Drobnes, Miklos Salgo, Adriano Lazzarin, Bonaventura Clotet, David Cooper, Jacques Reynes, Keikawus Arastéh, Mark Nelson, Christine Katlama, Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. The New England Journal of Medicine. ,vol. 348, pp. 2186- 2195 ,(2003) , 10.1056/NEJMOA035211
Roy M. Gulick, X. Joan Hu, Susan A. Fiscus, Courtney V. Fletcher, Richard Haubrich, Hailong Cheng, Edward Acosta, Stephen W. Lagakos, Ronald Swanstrom, William Freimuth, Sally Snyder, Charlotte Mills, Margaret Fischl, Carla Pettinelli, David Katzenstein, , Randomized Study of Saquinavir with Ritonavir or Nelfinavir Together with Delavirdine, Adefovir, or Both in Human Immunodeficiency Virus—Infected Adults with Virologic Failure on Indinavir: AIDS Clinical Trials Group Study 359 The Journal of Infectious Diseases. ,vol. 182, pp. 1375- 1384 ,(2000) , 10.1086/315867
Camlin Tierney, Janet L. Lathey, Cindy Christopherson, Daniel M. Bettendorf, Richard T. D’Aquila, Scott M. Hammer, David A. Katzenstein, , Prognostic Value of Baseline Human Immunodeficiency Virus Type 1 DNA Measurement for Disease Progression in Patients Receiving Nucleoside Therapy The Journal of Infectious Diseases. ,vol. 187, pp. 144- 148 ,(2003) , 10.1086/345870
Jacob P. Lalezari, Keith Henry, Mary O'Hearn, Julio S.G. Montaner, Peter J. Piliero, Benôit Trottier, Sharon Walmsley, Calvin Cohen, Daniel R. Kuritzkes, Joseph J. Eron, Jain Chung, Ralph DeMasi, Lucille Donatacci, Claude Drobnes, John Delehanty, Miklos Salgo, Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. The New England Journal of Medicine. ,vol. 348, pp. 2175- 2185 ,(2003) , 10.1056/NEJMOA035026
Jon H. Condra, Fred T. Valentine, Deborah McMahon, Charles Gonzalez, Leslie Jonas, Emilio A. Emini, Jeffrey A. Chodakewitz, Robin Isaacs, Douglas D. Richman, Roy M. Gulick, John W. Mellors, Diane Havlir, Joseph J. Eron, Anne Meibohm, 3-Year Suppression of HIV Viremia with Indinavir, Zidovudine, and Lamivudine Annals of Internal Medicine. ,vol. 133, pp. 35- 39 ,(2000) , 10.7326/0003-4819-133-1-200007040-00007
Roy M. Gulick, John W. Mellors, Diane Havlir, Joseph J. Eron, Charles Gonzalez, Deborah McMahon, Leslie Jonas, Anne Meibohm, Daniel Holder, William A. Schleif, Jon H. Condra, Emilio A. Emini, Robin Isaacs, Jeffrey A. Chodakewitz, Douglas D. Richman, Simultaneous vs Sequential Initiation of Therapy With Indinavir, Zidovudine, and Lamivudine for HIV-1 Infection: 100-Week Follow-up JAMA. ,vol. 280, pp. 35- 41 ,(1998) , 10.1001/JAMA.280.1.35